Irene Kazhdan
Medical Oncology · San Antonio, TXNPI 1649273145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,602 and has fallen 94.1% since, to $95 in 2021. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 147 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$278
- Novartis$238
- Johnson & Johnson$201
- Pfizer$194
- Lilly USA, LLC$155
- AstraZeneca$129
- plus $904 from 23 others
What the payments were for
- Food & beverage$2,07699%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $278 |
| Novartis | 15 | $238 |
| Johnson & Johnson(2 entities) | 5 | $201 |
| Pfizer | 36 | $194 |
| Lilly USA, LLC | 9 | $155 |
| AstraZeneca(2 entities) | 8 | $129 |
| Amgen | 5 | $107 |
| E.r. Squibb & Sons, L.L.C. | 7 | $100 |
| AbbVie | 4 | $76 |
| Eisai Inc. | 4 | $64 |
| Incyte Corporation | 4 | $57 |
| Puma Biotechnology, Inc. | 3 | $49 |
| EMD Serono, Inc. | 3 | $49 |
| Genentech USA, Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $43 |
| Sanofi | 2 | $39 |
| Bayer | 2 | $34 |
| Exelixis Inc. | 2 | $30 |
| Taiho Oncology, Inc. | 2 | $29 |
| Foundation Medicine, Inc. | 1 | $25 |
| Gilead | 2 | $24 |
| Array Biopharma Inc | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$125
How this compares
$2,098 in reported general payments places this provider in the 35th percentile of 495 medical oncology providers in Texas.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.